Cervical cancer vaccine approved by Chinese authorities
Initial shipments of Cervarix, the first vaccine for cervical cancer to be approved for use on the Chinese mainland, has passed inspection by Chinese quality authorities and is heading to health clinics across the country. Cervarix, developed by GSK, was approved by the China Food and Drug Administration in July last year. Cervarix has been registered in 132 countries and regions, and more than 69 million doses have been administered worldwide, according to GSK. A clinical trial in China, backed by CFDA and covering more than 6,000 females between 18 and 25 from 2008 to 2015, showed the vaccine generally to be more than 90 percent effective.
Because of its high cost, the vaccine may not be included in China’s national immunization plan. The three doses required for the vaccination may cost more than 1,700 yuan ($253) in China. Some Chinese companies are also researching vaccines for cervical cancer, and some are already the subject of clinical trials. It is expected that domestically made vaccines will be available at lower prices in the next few years, and eventually they may be included in the national vaccine program.